Details of Disease

General Information of Disease (ID: DISHF2X6)

Disease Name	Ulcer
Synonyms	ulcers; ulcer
Disease Class	CA02-CB40: Ulcer
Definition	A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
Disease Hierarchy	DISH7H5I: Human disease DISHF2X6: Ulcer
ICD Code	ICD-11 ICD-11: CA02-CB40 ICD-10 ICD-10: K25-K27 ICD-9 ICD-9: 531-534 Expand ICD-9 5.32E+11
Disease Identifiers	MONDO ID MONDO_0043839 MESH ID D014456 UMLS CUI C0041582 MedGen ID 22541 SNOMED CT ID 255321001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[1]
Ecabet sodium	DMLQ4FQ	Approved	Small molecular drug	[2]
Egualen sodium	DMDXRJP	Approved	Small molecular drug	[2]
Enprostil	DME9TWL	Approved	Small molecular drug	[3]
Ornoprostil	DM1DKYL	Approved	Small molecular drug	[2]
Plaunotol	DM02KMY	Approved	Small molecular drug	[2]
Polaprezinc	DM1OC6A	Approved	Small molecular drug	[2]
Rosaprostol	DME75MG	Approved	Small molecular drug	[2]
Sofalcone	DMVPLJ7	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

This Disease is Treated as An Indication in 5 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GC5101B	DMB5F09	Phase 3	NA	[4]
HP-011-101	DMOX2D8	Phase 2	NA	[5]
KUR-211	DM2N0Z3	Phase 2	NA	[6]
P-144	DMH81SR	Phase 2	NA	[7]
PDA-002	DMX60IL	Phase 2	NA	[8]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 2 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CYANIDIN CHLORIDE MONOHYDRATE	DMFUH7L	Discontinued in Phase 2	Small molecular drug	[9]
IO-21	DMSATO0	Discontinued in Phase 2	NA	[10]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 4 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BC-DU-04	DMT5VGJ	Investigative	NA	[11]
DWE-01	DM9V8X9	Investigative	NA	[11]
EG-Decorin	DMLY6W4	Investigative	NA	[11]
RO-17	DMUD304	Investigative	NA	[11]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 2 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
FGF2	TTGKIED	Strong	Biomarker	[13]
PPIF	TTRFQTB	Definitive	Biomarker	[14]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MX1	OT6X8G5T	Strong	Altered Expression	[15]
DDIT3	OTI8YKKE	Definitive	Biomarker	[14]
------------------------------------------------------------------------------------

References

1	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1918).
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	ClinicalTrials.gov (NCT01433159) Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury. U.S. National Institutes of Health.
6	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024804)
7	ClinicalTrials.gov (NCT00781053) Open Label Extension (OLE) for the Patients Treated in the ISD002-P144-07 Study. U.S. National Institutes of Health.
8	ClinicalTrials.gov (NCT02552277) A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.
9	A natural flavonoid, IdB 1027, increases gastric luminal release of prostaglandin E2 in healthy subjects. Ital J Gastroenterol. 1990 Oct;22(5):288-90.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002135)
11	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	Gastric mucosal injury activates bFGF gene expression and triggers preferential translation of high molecular weight bFGF isoforms through CUG-initiated, non-canonical codons.Biochem Biophys Res Commun. 2011 Jun 10;409(3):494-9. doi: 10.1016/j.bbrc.2011.05.033. Epub 2011 May 11.
14	Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin D protects from NSAID-induced small intestinal ulceration in mice.Toxicol Sci. 2010 Nov;118(1):276-85. doi: 10.1093/toxsci/kfq226. Epub 2010 Jul 28.
15	Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis.J Rheumatol. 2008 Nov;35(11):2192-200. doi: 10.3899/jrheum.080418. Epub 2008 Oct 1.